GB2617483B - Interleukin-18 variants and methods of use - Google Patents

Interleukin-18 variants and methods of use Download PDF

Info

Publication number
GB2617483B
GB2617483B GB2308183.9A GB202308183A GB2617483B GB 2617483 B GB2617483 B GB 2617483B GB 202308183 A GB202308183 A GB 202308183A GB 2617483 B GB2617483 B GB 2617483B
Authority
GB
United Kingdom
Prior art keywords
interleukin
variants
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2308183.9A
Other languages
English (en)
Other versions
GB202308183D0 (en
GB2617483A (en
Inventor
Ring Aaron
Boone Tom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Simcha Il 18 Inc
Yale University
Original Assignee
Simcha Il 18 Inc
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simcha Il 18 Inc, Yale University filed Critical Simcha Il 18 Inc
Publication of GB202308183D0 publication Critical patent/GB202308183D0/en
Publication of GB2617483A publication Critical patent/GB2617483A/en
Application granted granted Critical
Publication of GB2617483B publication Critical patent/GB2617483B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB2308183.9A 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use Active GB2617483B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108794P 2020-11-02 2020-11-02
PCT/US2021/057741 WO2022094473A1 (en) 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use

Publications (3)

Publication Number Publication Date
GB202308183D0 GB202308183D0 (en) 2023-07-19
GB2617483A GB2617483A (en) 2023-10-11
GB2617483B true GB2617483B (en) 2025-03-12

Family

ID=81384408

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2308183.9A Active GB2617483B (en) 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use

Country Status (14)

Country Link
US (3) US11850276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4236990A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550545A (cg-RX-API-DMAC7.html)
KR (1) KR20230117120A (cg-RX-API-DMAC7.html)
CN (1) CN116723851A (cg-RX-API-DMAC7.html)
AR (1) AR123978A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021371040C1 (cg-RX-API-DMAC7.html)
CA (1) CA3197145A1 (cg-RX-API-DMAC7.html)
GB (1) GB2617483B (cg-RX-API-DMAC7.html)
IL (1) IL302517A (cg-RX-API-DMAC7.html)
MX (1) MX2023005068A (cg-RX-API-DMAC7.html)
NZ (1) NZ800435A (cg-RX-API-DMAC7.html)
TW (1) TW202233657A (cg-RX-API-DMAC7.html)
WO (1) WO2022094473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7795181B2 (ja) 2017-09-06 2026-01-07 イェール ユニバーシティー インターロイキン-18バリアントとその利用法
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
EP4584287A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Il-18 variant polypeptides
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4655310A2 (en) * 2023-01-24 2025-12-03 Simcha Il-18, Inc. Methods and compositions for combination therapy
WO2024259270A2 (en) * 2023-06-16 2024-12-19 Simcha IL-18, Inc. Administration of engineered interleukin-18 therapeutics
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
CN120189493A (zh) * 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026050249A1 (en) * 2024-08-26 2026-03-05 Simcha IL-18, Inc. Methods of treating cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095946A1 (en) * 1997-02-25 2003-05-22 Matthew Todd Gillspie Il-18 as an osteoclastgenic inhibitor
US20080206189A1 (en) * 2003-04-15 2008-08-28 Smithkline Beecham Corporation Method of treating cancer by administering conjugates comprising human il-18 and substitution mutants thereof
US20120015891A1 (en) * 2010-01-04 2012-01-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
US20190070262A1 (en) * 2017-09-06 2019-03-07 Yale University Interleukin-18 variants and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
EP1669454A3 (en) 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP2007143555A (ja) * 1996-11-29 2007-06-14 Hayashibara Biochem Lab Inc ポリペプチド
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AU2001275166B2 (en) 2000-06-02 2005-07-28 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−18変異体、その産生および使用
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP2020143000A (ja) * 2019-03-04 2020-09-10 大陽日酸株式会社 融合タンパク質及びその製造方法、目的タンパク質の製造方法
US12029778B2 (en) * 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CN116368148A (zh) * 2020-08-19 2023-06-30 明峰治疗股份公司 修饰的il-18多肽及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095946A1 (en) * 1997-02-25 2003-05-22 Matthew Todd Gillspie Il-18 as an osteoclastgenic inhibitor
US20080206189A1 (en) * 2003-04-15 2008-08-28 Smithkline Beecham Corporation Method of treating cancer by administering conjugates comprising human il-18 and substitution mutants thereof
US20120015891A1 (en) * 2010-01-04 2012-01-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
US20190070262A1 (en) * 2017-09-06 2019-03-07 Yale University Interleukin-18 variants and methods of use

Also Published As

Publication number Publication date
US11850276B2 (en) 2023-12-26
AR123978A1 (es) 2023-02-01
MX2023005068A (es) 2023-07-14
EP4236990A1 (en) 2023-09-06
GB202308183D0 (en) 2023-07-19
WO2022094473A1 (en) 2022-05-05
JP2023550545A (ja) 2023-12-01
US12582701B2 (en) 2026-03-24
NZ800435A (en) 2025-12-19
US20230277625A1 (en) 2023-09-07
US20240066100A1 (en) 2024-02-29
TW202233657A (zh) 2022-09-01
AU2021371040C1 (en) 2025-05-29
AU2025203386A1 (en) 2025-06-05
US12564621B2 (en) 2026-03-03
KR20230117120A (ko) 2023-08-07
AU2021371040B2 (en) 2025-02-13
US20240075104A1 (en) 2024-03-07
EP4236990A4 (en) 2025-03-19
AU2021371040A1 (en) 2023-06-22
IL302517A (en) 2023-07-01
CA3197145A1 (en) 2022-05-05
GB2617483A (en) 2023-10-11
CN116723851A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
GB202308183D0 (en) Interleukin-18 variants and methods of use
IL272635A (en) Variants of interleukin-18 and methods of use
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL285285A (en) Pairs of il-2 and their uses
EP4045643A4 (en) CAS12A NUCLEASE VARIANTS AND METHODS OF MAKING AND USING THE SAME
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
IL304680A (en) Urolithin history and methods of using them
IL287973A (en) acss2 inhibitors and methods of their use
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL305834A (en) Phenalkylamines and methods for their preparation and use
IL314922A (en) Targeted cytokines and methods of using them
IL299245A (en) LAIR-1 binding agents and methods of using them
SI4200018T1 (sl) Protitelesa proti-PAR-2 in postopki njihove uporabe
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
IL298668B1 (en) Anti-CD200R1 antibodies and methods of using them
GB201919026D0 (en) Biocompatible adhesives and methods of manufacture thereof
IL305789A (en) USP30 inhibitors and uses thereof
IL313081A (en) New HDAC inhibitors and their medical use
GB202019767D0 (en) Compostitions and methods
IL310868A (en) Variants of interleukin-12 and methods of their use
GB202119051D0 (en) Wingsail and method of use
IL308683A (en) Peptides and methods of use
IL308260A (en) Antibodies against Tigit and methods of using them

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100273

Country of ref document: HK